Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma.
Halwani AS, Panizo C, Isufi I, Herrera AF, Okada CY, Cull EH, Kis B, Chaves JM, Bartlett NL, Ai W, de la Cruz-Merino L, Bryan LJ, Houot R, Linton K, Briones J, Chau I, von Keudell GR, Lu H, Yakovich A, Chen M, Meulen Jh T, Yurasov S, Hsu FJ, Flowers CR. Halwani AS, et al. Among authors: von keudell gr. Leuk Lymphoma. 2022 Apr;63(4):821-833. doi: 10.1080/10428194.2021.2010057. Epub 2021 Dec 6. Leuk Lymphoma. 2022. PMID: 34865586 Clinical Trial.
Follicular lymphoma.
Carbone A, Roulland S, Gloghini A, Younes A, von Keudell G, López-Guillermo A, Fitzgibbon J. Carbone A, et al. Nat Rev Dis Primers. 2019 Dec 12;5(1):83. doi: 10.1038/s41572-019-0132-x. Nat Rev Dis Primers. 2019. PMID: 31831752 Review.
Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma.
Moskowitz AJ, Shah G, Schöder H, Ganesan N, Drill E, Hancock H, Davey T, Perez L, Ryu S, Sohail S, Santarosa A, Galasso N, Neuman R, Liotta B, Blouin W, Kumar A, Lahoud O, Batlevi CL, Hamlin P, Straus DJ, Rodriguez-Rivera I, Owens C, Caron P, Intlekofer AM, Hamilton A, Horwitz SM, Falchi L, Joffe E, Johnson W, Lee C, Palomba ML, Noy A, Matasar MJ, Pongas G, Salles G, Vardhana S, Sanin BW, von Keudell G, Yahalom J, Dogan A, Zelenetz AD, Moskowitz CH. Moskowitz AJ, et al. J Clin Oncol. 2021 Oct 1;39(28):3109-3117. doi: 10.1200/JCO.21.01056. Epub 2021 Jun 25. J Clin Oncol. 2021. PMID: 34170745 Free PMC article. Clinical Trial.
Successful implementation of outpatient R ± DHAX (rituximab, dexamethasone, oxaliplatin, cytarabine) for select patients with lymphoma: a single-center experience.
Pak TK, Dixon BN, Buege MJ, Dao PH, Leary MH, Jarrett JC, Duggan TA, Caron P, Falchi L, Hamlin P, Hamilton A, Matasar MJ, Moskowitz A, Noy A, Owens CN, Von Keudell G, Younes A, Zelenetz AD, Kumar A. Pak TK, et al. Leuk Lymphoma. 2022 Apr;63(4):876-884. doi: 10.1080/10428194.2021.2002318. Epub 2021 Nov 16. Leuk Lymphoma. 2022. PMID: 34784853
Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma.
Sha F, Okwali M, Alperovich A, Caron PC, Falchi L, Hamilton A, Hamlin PA, Horwitz SM, Joffe E, Khan N, Kumar A, Matasar MJ, Moskowitz AJ, Noy A, Owens C, Palomba LM, Rodriguez-Rivera I, Straus D, von Keudell G, Zelenetz AD, Yahalom J, Dogan A, Schöder H, Seshan VE, Salles G, Younes A, Batlevi CL. Sha F, et al. Blood Cancer J. 2022 Feb 10;12(2):29. doi: 10.1038/s41408-022-00620-w. Blood Cancer J. 2022. PMID: 35145059 Free PMC article.
Will GALEN become more RELEVANT?
von Keudell G, Younes A. von Keudell G, et al. Lancet Haematol. 2019 Aug;6(8):e391-e392. doi: 10.1016/S2352-3026(19)30136-X. Epub 2019 Jul 8. Lancet Haematol. 2019. PMID: 31296424 No abstract available.
The Role of PI3K Inhibition in Lymphoid Malignancies.
von Keudell G, Moskowitz AJ. von Keudell G, et al. Curr Hematol Malig Rep. 2019 Oct;14(5):405-413. doi: 10.1007/s11899-019-00540-w. Curr Hematol Malig Rep. 2019. PMID: 31359259 Review.
30 results